A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Chickenpox

Interventions

BIOLOGICAL: Candidate varicella vaccine
BIOLOGICAL: Marketed varicella vaccine
BIOLOGICAL: MMR vaccine
BIOLOGICAL: Hepatitis A vaccine
BIOLOGICAL: PCV (pneumococcal conjugate vaccine) 13
BIOLOGICAL: PCV 20
BIOLOGICAL: Vaxneuvance

Sponsor

GlaxoSmithKline